Sleep Disorders

Adults with obstructive sleep apnea who receivied tirzepatide achieved an average of up to 20% weight loss and experienced at least 25 fewer breathing interruptions for each hour slept.

The cumulative incidence of dementia was higher in people with OSA, particularly for women, across different age groups.

Although the study was limited, the data warrant further research and a raised awareness of the elevated risk associated with sleep apnea comorbidities in younger patients with epilepsy.

Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.

The vice chair of the American Academy of Sleep Medicine’s Clinical Practice Guidelines Task Force commented on some of the unanswered questions following the recently published guidelines for restless legs syndrome. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on parasomnias.

Shalini Paruthi, MD, FAASM, a spokesperson for the American Academy of Sleep Medicine, provided a clinical overview on restless leg syndrome for diagnosing and tailoring treatment for patients with the condition.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Andy Berkowski, MD, PhD. [LISTEN TIME: 26 minutes]

Over the 6-month treatment period, patients saw improvements in cataplexy frequency, excessive daytime sleepiness, cognition, and work productivity with AXS-12.

The vice chair of the American Academy of Sleep Medicine’s Clinical Practice Guidelines Task Force provided in-depth insight on the most noted changes to the 2024 RLS guidelines clinicians should be aware of. [WATCH TIME: 9 minutes]

In a previously completed phase 1 study, the treatment resulted in significant improvements in wakefulness at doses of 1.0 mg and 2.5 mg, prompting a follow-up study.

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital talked about how the recent approval of once-nightly sodium oxybate for pediatric narcolepsy enables more effective and manageable treatment options for children and families.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne Marie Morse, DO, FAASM. [LISTEN TIME: 12 minutes]

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital provided her immediate reaction to the approval of a once-nightly sodium oxybate for pediatric narcolepsy. [WATCH TIME: 7 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital talked about the new clinical guidelines for treating restless legs syndrome which emphasize the risks of dopamine agonists and advocate for alternative therapies. [WATCH TIME: 8 minutes]

Neurology News Network. for the week ending October 19, 2024. [WATCH TIME: 4 minutes]

Sodium oxybate is the only FDA-approved once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in pediatric patients with narcolepsy.

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the newly updated treatment guidelines for the treatment of restless legs syndrome.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Alzheimer disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on insomnia.

Sleep is critical for physical and mental health, with its insufficiency leading to various disorders and increased health risks; thus, clinicians should integrate sleep assessments and hygiene strategies into their clinical care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 27, 2024.

In the phase 1 trial, the 2.5 mg dose of ORX750 significantly improved wakefulness, restoring normal sleep latency to 32 minutes compared to placebo.

Here's some of what is coming soon to NeurologyLive® this week.